Payment overview · 2025
General Payments
$421.76
22 reported records · 6 companies
Healthcare provider profile · identity verified
John Matthew Commet, DO
Allopathic & Osteopathic Physicians|Family Medicine · FLUSHING, MI · NPI 1437178225
Verified facts
What the public records show
CMS Open Payments records show John Matthew Commet, DO received $421.76 in general payments during 2025 across 22 reported records.
Astellas Pharma US Inc accounted for 44.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $186.51 | 44.2% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.34 | 17.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.16 | 16.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.91 | 14.4% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.15 | 3.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.69 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $339.77 | 21 |
| Education | $81.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $104.52 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $70.16 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.18 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.35 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.82 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.86 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 185 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
185 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 623 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 437 | 123 |
| Lisinopril | Lisinopril | 295 | 85 |
| Omeprazole | Omeprazole | 234 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 67 |
| Jardiance | Empagliflozin | 196 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 56 |
| Simvastatin | Simvastatin | 189 | 54 |
| Eliquis | Apixaban | 185 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 48 |
| Potassium Chloride | Potassium Chloride | 162 | 61 |
| Mounjaro | Tirzepatide | 159 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 44 |
| Metformin Hcl | Metformin Hcl | 136 | 40 |
| Losartan Potassium | Losartan Potassium | 134 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 48 |
| Prednisone | Prednisone | 122 | 78 |
| Famotidine | Famotidine | 118 | 45 |
| Allopurinol | Allopurinol | 117 | 35 |
| Bupropion Xl | Bupropion Hcl | 115 | 23 |
| Montelukast Sodium | Montelukast Sodium | 115 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 33 |
| Valsartan | Valsartan | 112 | 31 |
| Finasteride | Finasteride | 104 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 19 |
| Metformin Hcl Er | Metformin Hcl | 99 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 21 |
| Alprazolam | Alprazolam | 88 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 25 |
| Ozempic | Semaglutide | 84 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 82 | 20 |
| Sertraline Hcl | Sertraline Hcl | 80 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 21 |
| Farxiga | Dapagliflozin Propanediol | 78 | 18 |
| Furosemide | Furosemide | 75 | 27 |
| Trazodone Hcl | Trazodone Hcl | 74 | 23 |
| Atenolol | Atenolol | 73 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 20 |
| Xarelto | Rivaroxaban | 71 | 19 |
| Gabapentin | Gabapentin | 70 | 18 |
| Trulicity | Dulaglutide | 67 | 15 |
| Glimepiride | Glimepiride | 64 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 26 |
| Irbesartan | Irbesartan | 63 | 18 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 61 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 12 |
| Torsemide | Torsemide | 60 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 59 | 18 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 53 | 16 |
| Carvedilol | Carvedilol | 51 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Celecoxib | Celecoxib | 47 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 14 |
| Methylprednisolone | Methylprednisolone | 46 | 41 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 16 |
| Ezetimibe | Ezetimibe | 44 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 11 |
| Dutasteride | Dutasteride | 43 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 14 |
| Calcitriol | Calcitriol | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 14 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Testosterone | Testosterone | 38 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | 13 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 12 |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | 14 |
| Januvia | Sitagliptin Phosphate | 33 | 11 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | 15 |
| Valacyclovir | Valacyclovir Hcl | 31 | 15 |
| Baclofen | Baclofen | 30 | 15 |
| Cefdinir | Cefdinir | 30 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 30 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 19 |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 12 |
| Acyclovir | Acyclovir | 25 | 13 |
| Amoxicillin | Amoxicillin | 23 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Cefadroxil | Cefadroxil | 20 | 16 |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 14 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 14 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Cefprozil | Cefprozil | 13 | 12 |
| Fluconazole | Fluconazole | 13 | 12 |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Prevalite | Cholestyramine | 12 | suppressed |
| Riluzole | Riluzole | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Cefixime | Cefixime | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $421.76 · 22 records | Astellas Pharma US Inc | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, ELIQUIS, Korlym, NURTEC ODT, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, UBRELVY, Veozah, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error